Gordon B Mills Selected Research

QLT 0267

1/2007	Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck.
11/2005	Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.
8/2005	Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gordon B Mills Research Topics

Disease

450	Neoplasms (Cancer) 07/2022 - 02/2002
140	Breast Neoplasms (Breast Cancer) 07/2022 - 04/2003
85	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2002
33	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2002
32	Carcinogenesis 11/2018 - 03/2003
27	Melanoma (Melanoma, Malignant) 10/2021 - 08/2006
23	Carcinoma (Carcinomatosis) 04/2022 - 02/2002
19	Squamous Cell Carcinoma of Head and Neck 04/2022 - 04/2006
19	Endometrial Neoplasms (Endometrial Cancer) 04/2022 - 07/2011
17	Triple Negative Breast Neoplasms 10/2021 - 04/2012
14	Ovarian Epithelial Carcinoma 05/2020 - 07/2003
11	Ascites 11/2020 - 02/2002
11	Lung Neoplasms (Lung Cancer) 01/2020 - 06/2003
8	Residual Neoplasm 05/2022 - 02/2012
8	Pancreatic Neoplasms (Pancreatic Cancer) 03/2022 - 10/2002
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 03/2006
8	Head and Neck Neoplasms (Head and Neck Cancer) 10/2021 - 04/2006
7	Glioma (Gliomas) 01/2022 - 04/2002
7	Hypoxia (Hypoxemia) 01/2019 - 02/2012
6	Bites and Stings (Sting) 01/2022 - 01/2019
6	Disease Progression 11/2020 - 05/2006
6	Stomach Neoplasms (Stomach Cancer) 01/2020 - 01/2011
6	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 09/2007
6	Obesity 12/2017 - 02/2011
5	Leukemia 01/2022 - 04/2006
5	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 03/2002
5	Prostatic Neoplasms (Prostate Cancer) 12/2018 - 12/2007

Drug/Important Bio-Agent (IBA)

162	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2003
67	Biomarkers (Surrogate Marker)IBA 05/2022 - 01/2003
47	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 11/2004
43	Pharmaceutical PreparationsIBA 01/2022 - 05/2004
38	Messenger RNA (mRNA)IBA 10/2021 - 04/2003
35	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2003
35	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020 - 04/2003
32	Phosphotransferases (Kinase)IBA 01/2022 - 01/2003
31	Estrogen ReceptorsIBA 01/2020 - 04/2009
24	Hormones (Hormone)IBA 11/2019 - 04/2003
23	Biological ProductsIBA 10/2021 - 06/2009
23	Small Interfering RNA (siRNA)IBA 08/2021 - 03/2006
21	lysophosphatidic acidIBA 04/2017 - 05/2002
20	Estrogens (Estrogen)FDA Link 01/2021 - 08/2007
18	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2022 - 08/2010
18	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 06/2003
18	MicroRNAs (MicroRNA)IBA 01/2021 - 03/2009
17	PlatinumIBA 01/2021 - 05/2008
16	EnzymesIBA 01/2022 - 03/2003
15	ErbB Receptors (EGF Receptor)IBA 10/2021 - 05/2003
15	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2020 - 02/2002
14	Phenobarbital (Luminal)FDA Link 01/2019 - 05/2009
13	Immune Checkpoint InhibitorsIBA 01/2022 - 11/2017
12	ProteomeIBA 01/2020 - 12/2010
12	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2019 - 04/2002
12	Lysophosphatidic Acid ReceptorsIBA 06/2010 - 01/2002
11	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 04/2003
11	TOR Serine-Threonine KinasesIBA 01/2016 - 04/2003
11	LipidsIBA 01/2016 - 04/2002
10	Trastuzumab (Herceptin)FDA Link 01/2021 - 10/2003
10	Sirolimus (Rapamycin)FDA Link 01/2021 - 02/2004
10	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 04/2003
9	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2021 - 05/2009
9	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 05/2003
9	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 03/2010
9	CytokinesIBA 01/2018 - 03/2004
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 09/2003
8	AntibodiesIBA 01/2020 - 03/2004
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 02/2002
8	Indicators and Reagents (Reagents)IBA 09/2017 - 04/2003
8	PhosphoproteinsIBA 01/2017 - 01/2009
7	Drug CombinationsIBA 07/2022 - 03/2009
7	MK 2206IBA 04/2022 - 10/2012
7	Tamoxifen FDA LinkGeneric 01/2021 - 08/2008
7	IntegrinsIBA 12/2020 - 10/2007
7	Fulvestrant (Faslodex)FDA Link 01/2020 - 05/2009
7	src-Family KinasesIBA 10/2018 - 01/2003
7	Tyrosine Kinase InhibitorsIBA 10/2018 - 05/2003
7	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2017 - 01/2003
7	Interleukin-8 (Interleukin 8)IBA 06/2013 - 09/2003
6	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2021 - 01/2017
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 02/2006
6	Epidermal Growth Factor (EGF)IBA 10/2019 - 08/2005
6	Protein Isoforms (Isoforms)IBA 07/2018 - 06/2003
6	ParaffinIBA 10/2016 - 02/2009
6	Formaldehyde (Formol)FDA Link 10/2016 - 02/2009
6	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 10/2014 - 10/2004
6	Monomeric GTP-Binding ProteinsIBA 02/2012 - 05/2003
6	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 05/2009 - 02/2002
5	Cetuximab (Erbitux)FDA Link 10/2021 - 12/2004
5	AntigensIBA 01/2021 - 09/2009
5	NucleotidesIBA 12/2019 - 08/2006
5	Long Noncoding RNAIBA 10/2017 - 09/2014
5	CyclinsIBA 01/2017 - 05/2006
5	MTOR InhibitorsIBA 04/2016 - 04/2005
5	Transcription Factors (Transcription Factor)IBA 08/2015 - 03/2004
5	TensinsIBA 09/2014 - 03/2006
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014 - 05/2003

Therapy/Procedure

202	Therapeutics 07/2022 - 01/2002
43	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
19	Immunotherapy 07/2022 - 10/2016
11	Neoadjuvant Therapy 04/2022 - 04/2011
10	Precision Medicine 01/2022 - 05/2013